₹7,543 crore, according to analysts.Dr V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services while expressing his views on FPI data said, "In view of the strong dollar and high US bond yields FPIs may continue to sell in India. Also, since the markets have rallied smartly during the last three months, some profit booking by FPIs would be rational and can be expected."On August 12, Aurobindo Pharma released its financial results for the April-June quarter of fiscal year 2023-24 (Q1FY24).
The report outlined a decrease of 22.5% in net profit, which amounted to ₹540 crore in contrast to the ₹697.6 crore recorded during the corresponding period in the previous year. However, the pharmaceutical major's revenue from operations during the initial quarter of the current fiscal year showed a positive trajectory, reaching ₹6,850.5 crore.
This represented a growth of 9.9% compared to the figure of ₹6,236 crore in the same period of the preceding year.The company's performance on the operational front exhibited improvement in the June quarter, with its earnings before interest, taxes, depreciation, and amortization (EBITDA) surging by almost 23% to ₹1,151.4 crore. This was in contrast to the ₹936.5 crore recorded during the same period in the previous year.
Furthermore, the EBITDA margin expanded to 16.8% in the quarter under review, a notable increase from the 15% observed in the corresponding quarter of the previous year. (Read More)On August 11, Oil and Natural Gas Corporation (ONGC) unveiled its financial results for the April-June quarter of fiscal year 2023-24 (Q1FY24).
Read more on livemint.com